CDKN2A Antibody / p16INK4a [clone rCDKN2A/4845] (V9523)

Catalog No.	Formulation	Size
V9523-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	100 ug
V9523-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	20 ug
V9523SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug

Recombinant MOUSE MONOCLONAL

Bulk quote request

Availability	1-3 business days
Species Reactivity	Human
Format	Purified
Host	Mouse
Clonality	Recombinant Mouse Monoclonal
Isotype	Mouse IgG2a, kappa
Clone Name	rCDKN2A/4845
Purity	Protein A/G affinity
UniProt	P42771
Localization	Nucleus, Cytoplasm
Applications	Western Blot : 1-2ug/ml Immunohistochemistry (FFPE) : 1-2ug/ml
Limitations	This CDKN2A antibody is available for research use only.



CDKN2A Antibody HepG2 WB. Western blot testing of human HepG2 cell lysate using CDKN2A antibody (clone rCDKN2A/4845). Predicted molecular weight ~16 kDa.



CDKN2A Antibody Cervix IHC. Immunohistochemistry staining of FFPE human cervical tissue with CDKN2A antibody (clone rCDKN2A/4845). HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.



CDKN2A Antibody Human Cervix Tissue IHC. staining of FFPE human cervix with CDKN2A antibody (clone rCDKN2A/4845). HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.



CDKN2A Antibody HeLa WB. Western blot analysis of Cyclin-dependent kinase inhibitor 2A (p16INK4a) expression in human HeLa cell lysate using CDKN2A Antibody clone rCDKN2A/4845. Lane 1: HeLa cell lysate. A band is detected at approximately 15-17 kDa, consistent with the predicted molecular weight of p16INK4a, a cyclin-dependent kinase inhibitor that regulates G1 cell cycle progression through inhibition of CDK4 and CDK6.

Description

p16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype.

This antibody is part of a broader antibody panel offered by NSJ Bioreagents.

Application Notes

Optimal dilution of the CDKN2A antibody should be determined by the researcher.

Immunogen

Purified recombinant prokaryotic full-length human p16INK4a protein was used as the immunogen for the CDKN2A antibody.

Storage

Aliquot the CDKN2A antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.